Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia

被引：3

作者：

Haddad, Fadi ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Issa, Ghayas C. ^{[1
]}

Jabbour, Elias ^{[1
]}

Sasaki, Koji ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA

来源：

LEUKEMIA & LYMPHOMA | 2022年 / 63卷 / 07期

关键词：

PERIPHERAL NEUROPATHY; IMATINIB; DASATINIB; THERAPY; EDEMA;

D O I：

10.1080/10428194.2022.2045599

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1714 / 1717

页数：4

共 50 条

[11] Characterization of the Genomic Landscape of BCR-ABL1 Kinase-Independent Mechanisms of Resistance to ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
Eide, Christopher A.
Bottomly, Daniel
Savage, Samantha L.
White, Libbey
Wilmot, Beth
Schultz, Anna M. Reister
Uchida, Kimberly A.
Agarwal, Anupriya
Traer, Elie
Beppu, Lan
Sala-Torra, Olga
Radich, Jerald P.
Eickelberg, Garrett
Press, Richard D.
Loriaux, Marc M.
Tantravahi, Srinivas K.
Pomicter, Anthony D.
Zabriskie, Matthew S.
Deininger, Michael W.
O'Hare, Thomas
Tyner, Jeffrey W.
McWeeney, Shannon K.
Tognon, Cristina E.
Druker, Brian J.
[J]. BLOOD, 2016, 128 (22)
[12] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
Pinilla-Ibarz, Javier
Sweet, Kendra
Emole, Josephine
Fradley, Michael
[J]. ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
[13] Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors
Kim, Sung-Hyun
Menon, Hari
Jootar, Saengsuree
Saikia, Tapan
Kwak, Jae-Yong
Sohn, Sang-Kyun
Park, Joon Seong
Jeong, Seong Hyun
Kim, Hyeoung Joon
Kim, Yeo-Kyeoung
Oh, Suk Joong
Kim, Hawk
Zang, Dae Young
Chung, Joo Seop
Shin, Ho Jin
Do, Young Rok
Kim, Jeong-A
Kim, Dae-Young
Choi, Chul Won
Park, Sahee
Park, Hye Lin
Lee, Gong Yeal
Cho, Dae Jin
Shin, Jae Soo
Kim, Dong-Wook
[J]. HAEMATOLOGICA, 2014, 99 (07) : 1191 - 1196
[14] PREDICTIVE FACTORS FOR OUTCOME TO NOVEL BCR-ABL1 TYROSINE KINASE INHIBITORS IN IMATINIB FAILED CHRONIC PHASE CHRONIC MYELOID LEUKEMIA
Lee, S. E.
Choi, S. Y.
Kim, S. H.
Oh, Y. J.
Chae, M. J.
Song, H. Y.
Yoo, H. L.
Lee, M. Y.
Jang, E. J.
Jeong, K. H.
Lee, J. S.
Kim, D. W.
[J]. HAEMATOLOGICA, 2014, 99 : 336 - 336
[15] Discontinuation of tyrosine kinase inhibitors based on BCR-ABL1 monitoring by digital droplet PCR in pediatric chronic myeloid leukemia
Kim, Yeojae
Kim, Seongkoo
Lee, Jong Mi
Ahn, Ari
Yoo, Jae Won
Lee, Jae Wook
Cho, Bin
Chung, Nack-Gyun
Kim, Yonggoo
Kim, Myungshin
[J]. FRONTIERS IN PEDIATRICS, 2022, 10
[16] Chronic Myeloid Leukemia: Beyond BCR-ABL1
Zhou, Ting
Medeiros, L. Jeffrey
Hu, Shimin
[J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2018, 13 (06) : 435 - 445
[17] Chronic Myeloid Leukemia: Beyond BCR-ABL1
Ting Zhou
L. Jeffrey Medeiros
Shimin Hu
[J]. Current Hematologic Malignancy Reports, 2018, 13 : 435 - 445
[18] Mutations in the BCR-ABL1 Kinase Domain and Elsewhere in Chronic Myeloid Leukemia
Soverini, Simona
de Benedittis, Caterina
Mancini, Manuela
Martinelli, Giovanni
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S120 - S128
[19] Successful treatment with ABL tyrosine kinase inhibitor for patients with acute myeloid leukemia with BCR-ABL1
Takeuchi, Asako
Kondo, Toshinori
Tasaka, Taizo
Yamada, Seiko
Hirose, Tadashi
Fukuda, Hirofumi
Shimizu, Risa
Matsuhashi, Yoshiko
Kondo, Eisei
Wada, Hideho
[J]. LEUKEMIA RESEARCH REPORTS, 2021, 15
[20] Mutation analysis of BCR-ABL1 kinase domain in chronic myeloid leukemia patients with tyrosine kinase inhibitors resistance: a Malaysian cohort study
Abu Seman, Zahidah
Ahid, Fadly
Kamaluddin, Nor Rizan
Sahid, Ermi Neiza Mohd
Esa, Ezalia
Said, Siti Shahrum Muhamed
Azman, Norazlina
Mat, Wan Khairull Dhalila Wan
Abdullah, Julia
Ali, Nurul Aqilah
Khalid, Mohd Khairul Nizam Mohd
Yusoff, Yuslina Mat
[J]. BMC RESEARCH NOTES, 2024, 17 (01)

← 1 2 3 4 5 →